Eupraxia Pharmaceuticals (EPRX) Long-Term Debt Repayments (2023 - 2024)

Eupraxia Pharmaceuticals (EPRX) posted quarterly Long-Term Debt Repayments of $18.1 million for Q4 2024, up 496.28% quarter-over-quarter from -$4.6 million in Q3 2024.

Eupraxia Pharmaceuticals (EPRX) Long-Term Debt Repayments (2023 - 2024) Analysis & Trends

Eupraxia Pharmaceuticals (EPRX) has reported Long-Term Debt Repayments for 2 consecutive years, with $18.1 million the latest figure, recorded in Q4 2024.

  • In Q4 2024, Long-Term Debt Repayments changed N/A year-over-year to $18.1 million; the TTM figure through Dec 2024 stood at $9.1 million (changed N/A YoY), while the FY2024 annual figure was $9.1 million, changed N/A from the prior year.
  • Long-Term Debt Repayments rose to $18.1 million in Q4 2024 per EPRX's latest filing, from -$4.6 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $18.1 million in Q4 2024 and bottomed at -$4.6 million in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 17.05 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Eupraxia Pharmaceuticals 381.11 Mn 379.51 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 18.15 Mn
Dec 31, 2024 18.15 Mn
Sep 30, 2024 -4.58 Mn
Sep 30, 2024 -4.58 Mn
Jun 30, 2024 -4.47 Mn
Jun 30, 2024 -4.47 Mn
Mar 31, 2024 -20,547.00
Mar 31, 2024 -20,547.00
Sep 30, 2023 -19,992.00
Sep 30, 2023 -19,992.00
Jun 30, 2023 -19,751.00
Jun 30, 2023 -19,751.00
Mar 31, 2023 -19,400.00
Mar 31, 2023 -19,400.00